Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Norway
  4. Oslo Bors
  5. BerGenBio ASA
  6. News
  7. Summary
    BGBIO   NO0010650013

BERGENBIO ASA

(BGBIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

BerGenBio ASA: Share capital increase

09/06/2021 | 03:38am EDT
Bergen, Norway, 6 September 2021 - Reference is made to the stock exchange
notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 31 August 2021
where the Company announced that the board of directors of the Company had
resolved to increase the Company's share capital in connection with the exercise
of options pursuant to the Company's share option program. A total of 15,000
options were exercised and 15,000 new shares were issued at an average
subscription price of NOK 10.62 per share.

The share capital increase has been duly registered in the Norwegian Register of
Business Enterprises. Following such registration, the Company's share capital
is NOK 8,824,775.50 divided into 88,247,755 shares, each with a nominal value of
NOK 0.10.

-End-

Contacts

Rune Skeie

Interim CEO and CFO, BerGenBio ASA

Rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange

All news about BERGENBIO ASA
10/04BERGENBIO ASA : Share capital increase
AQ
10/01BERGENBIO : Announces poster presentation at society for immunotherapy of cancerá(sitc) an..
AQ
09/30BERGENBIO ASA : Increase of share capital, exercise of share options
AQ
09/30BERGENBIO ASA : Increase of share capital, exercise of share options
AQ
09/08BERGENBIO : Recruits 86 Patients For Phase II Trial Of Leukemia Drug
MT
09/07BERGENBIO : Completes recruitment of phase ii aml study (bgbc003)
AQ
09/07BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003)
CI
09/06BERGENBIO ASA : Share capital increase
AQ
08/31BERGENBIO ASA : Increase of share capital, exercise of share options
AQ
08/26BERGENBIO ASA : Share capital increase
AQ
More news
Financials
Sales 2021 - - -
Net income 2021 -345 M -41,0 M -41,0 M
Net cash 2021 394 M 46,8 M 46,8 M
P/E ratio 2021 -5,13x
Yield 2021 -
Capitalization 1 777 M 211 M 211 M
EV / Sales 2021 -
EV / Sales 2022 5,27x
Nbr of Employees 46
Free-Float 57,6%
Chart BERGENBIO ASA
Duration : Period :
BerGenBio ASA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BERGENBIO ASA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 20,10 NOK
Average target price 56,33 NOK
Spread / Average Target 180%
EPS Revisions
Managers and Directors
Martin Olin Chief Executive Officer
Rune Skeie Chief Financial Officer
Sveinung Hole Chairman
Alison Messom Director-Clinical Operations
E. Gwyn Thomas Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BERGENBIO ASA-37.58%211
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156